The disease mimicked the aggressive variant of human CLL, characterized by the appearance of prolymphocytes (141) (Figure 2), suggesting that TIR8/SIGIRR acts as an inhibitor of CLL progression through a still unclear molecular mechanism. Here, SIGIRR is linked to B-cell chronic lymphocytic leukemia.